Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus TACE versus TACE alone for advanced hepatocellular carcinoma
ChiCTR1900020699Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Nanchang University. Started Jan 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900020699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020699.